Translational impact of omics studies in alopecia areata: recent advances and future perspectives

References

• Mirzoyev SA, Schrum AG, Davis MDP, et al. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester epidemiology project, 1990-2009. J Invest Dermatol. 2014 Apr;134:1141–1142.
   PubMed Web of Science ®Google Scholar
• Harries M, Macbeth AE, and Holmes S, et al. The epidemiology of alopecia areata: a population-based cohort study in UK primary care. Br J Dermatol. 2022 Feb;186:257–265.
   PubMedGoogle Scholar
• Okhovat JP, Marks DH, Manatis-Lornell A, et al. Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis. J Am Acad Dermatol. 2019 Jun 1. DOI:https://doi.org/10.1016/j.jaad.2019.05.086.
   Google Scholar
• Tzur Bitan D, Berzin D, and Kridin K, et al. The association between alopecia areata and anxiety, depression, schizophrenia, and bipolar disorder: a population-based study. Arch Dermatol Res. 2022;314:463–468.
   PubMedGoogle Scholar
• Tzur Bitan D, Berzin D, Kridin K, et al. Alopecia areata as a proximal risk factor for the development of comorbid depression: a population-based study. Acta Derm Venereol. 2022 Mar 14;102:adv00669.
   PubMedGoogle Scholar
• Macbeth AE, Holmes S, Harries M, et al. The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care. Br J Dermatol. 2022 Feb 14. DOI:https://doi.org/10.1111/bjd.21055.
   Google Scholar
• Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol. 2006;55:438–441.
   PubMed Web of Science ®Google Scholar
• Lyakhovitsky A, Aronovich A, Gilboa S, et al. Alopecia areata: a long-term follow-up study of 104 patients. J Eur Acad Dermatol Venereol. 2019;33:1602–1609.
   PubMedGoogle Scholar
• Folster-Holst R, Rohrer T, Jung AM. Dermatological aspects of the S2k guidelines on down syndrome in childhood and adolescence. J Dtsch Dermatol Ges. 2018;16:1289–1295.
   Google Scholar
• Chelidze K, Lipner SR. Nail changes in alopecia areata: an update and review. Int J Dermatol. 2018;57:776–783.
   PubMed Web of Science ®Google Scholar
• Pratt CH, King LE Jr., Messenger AG, et al. Alopecia areata. Nat Rev Dis Primers. 2017 16;3:17011.
   PubMed Web of Science ®Google Scholar
• Huang KP, Mullangi S, Guo Y, et al. Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol. 2013 Jul;149:789–794.
   PubMed Web of Science ®Google Scholar
• Hordinsky M, Ericson M. Autoimmunity: alopecia areata. J Investig Dermatol Symp Proc. 2004;9:73–78.
   PubMed Web of Science ®Google Scholar
• Paus R, Bulfone-Paus S, Bertolini M. Hair follicle immune privilege revisited: the key to alopecia areata management. J Investig Dermatol Symp Proc. 2018;19:S12–7.
   PubMedGoogle Scholar
• Bertolini M, McElwee K, Gilhar A, et al. Hair follicle immune privilege and its collapse in alopecia areata. Exp Dermatol. 2020;29:703–725.
   PubMed Web of Science ®Google Scholar
• Ito T, Ito N, Saatoff M, et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol. 2008;128:1196–1206.
   PubMed Web of Science ®Google Scholar
• Paus R, Nickoloff BJ, Ito T. A ‘hairy’ privilege. Trends Immunol. 2005;26:32–40.
   PubMed Web of Science ®Google Scholar
• Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83:123–130.
   PubMed Web of Science ®Google Scholar
• Lintzeri DA, Constantinou A, Hillmann K, et al. Alopecia areata - Current understanding and management. J Dtsch Dermatol Ges. 2022;20:59–90.
   Google Scholar
• Xing L, Dai Z, and Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20:1043–1049.
   PubMed Web of Science ®Google Scholar
• Petukhova L, Duvic M, and Hordinsky M, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010 1;466(7302):113–117.
   PubMed Web of Science ®Google Scholar
• Waskiel-Burnat A, Osinska M, Salinska A, et al. The role of serum Th1, Th2, and Th17 cytokines in patients with Alopecia areata: clinical implications. Cells. 2021 2;10(12):3397.
   PubMedGoogle Scholar
• Gilhar A, Laufer Britva R, Keren A, et al. Mouse models of alopecia areata: C3H/HeJ mice versus the humanized AA mouse model. J Investig Dermatol Symp Proc. 2020;20:S11–5.
   PubMedGoogle Scholar
• Betz RC, Konig K, Flaquer A, et al. The R620W polymorphism in PTPN22 confers general susceptibility for the development of alopecia areata. Br J Dermatol. 2008;158:389–391.
   PubMed Web of Science ®Google Scholar
• Betz RC, Pforr J, Flaquer A, et al. Loss-of-function mutations in the filaggrin gene and alopecia areata: strong risk factor for a severe course of disease in patients comorbid for atopic disease. J Invest Dermatol. 2007;127:2539–2543.
   PubMedGoogle Scholar
• John KK, Brockschmidt FF, Redler S, et al. Genetic variants in CTLA4 are strongly associated with alopecia areata. J Invest Dermatol. 2011;131:1169–1172.
   PubMed Web of Science ®Google Scholar
• Tazi-Ahnini R, Cork MJ, Gawkrodger DJ, et al. Role of the autoimmune regulator (AIRE) gene in alopecia areata: strong association of a potentially functional AIRE polymorphism with alopecia universalis. Tissue Antigens. 2002;60:489–495.
   PubMed Web of Science ®Google Scholar
• Betz RC, Petukhova L, Ripke S, et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun. 2015;6:5966.
   PubMed Web of Science ®Google Scholar
• Jagielska D, Redler S, Brockschmidt FF, et al. Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance. J Invest Dermatol. 2012;132:2192–2197.
   PubMed Web of Science ®Google Scholar
• Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271–275.
   PubMed Web of Science ®Google Scholar
• Pan F, Yu H, Dang EV, et al. Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science. 2009;325:1142–1146.
   PubMed Web of Science ®Google Scholar
• Monteleone G, Pallone F, Macdonald TT. Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol Sci. 2009;30:441–447.
   PubMed Web of Science ®Google Scholar
• Nusslein HG, Alten R, Galeazzi M, et al. Efficacy and prognostic factors of treatment retention with intravenous Abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. Clin Exp Rheumatol. 2016;34:489–499.
   PubMed Web of Science ®Google Scholar
• Sundberg JP, McElwee KJ, Carroll JM, et al. Hypothesis testing: CTLA4 co-stimulatory pathways critical in the pathogenesis of human and mouse alopecia areata. J Invest Dermatol. 2011;131:2323–2324.
   PubMed Web of Science ®Google Scholar
• Eagle RA, Traherne JA, Hair JR, et al. ULBP6/RAET1L is an additional human NKG2D ligand. Eur J Immunol. 2009;39:3207–3216.
   PubMed Web of Science ®Google Scholar
• Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol. 2007;7:737–744.
   PubMed Web of Science ®Google Scholar
• Moftah NH, El-Barbary RA, Rashed L, et al. ULBP3: a marker for alopecia areata incognita. Arch Dermatol Res. 2016;308:415–421.
   PubMedGoogle Scholar
• Wang ECE, Dai Z, Christiano AM. Novel therapies for alopecia areata: the era of rational drug development. J Allergy Clin Immunol. 2018;141:499–504.
   PubMedGoogle Scholar
• Wang R, Kozhaya L, Mercer F, et al. Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A. 2009;106:13439–13444.
   PubMed Web of Science ®Google Scholar
• Battaglia M, Roncarolo MG. The Tregs’ world according to GARP. Eur J Immunol. 2009;39:3296–3300.
   PubMedGoogle Scholar
• Boyle EA, Li YI, Pritchard JK. An expanded view of complex traits: from polygenic to omnigenic. Cell. 2017;169:1177–1186.
   PubMed Web of Science ®Google Scholar
• Lupski JR, Belmont JW, Boerwinkle E, et al. Clan genomics and the complex architecture of human disease. Cell. 2011;147:32–43.
   PubMedGoogle Scholar
• GTEx Consortium, Laboratory, Data Analysis &Coordinating Center (LDACC)—Analysis Working Group, Statistical Methods groups—Analysis Working Group, et al. Genetic effects on gene expression across human tissues. Nature. 2017;550:204–213.
   Google Scholar
• Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science. 2012;337:1190–1195.
   PubMed Web of Science ®Google Scholar
• Petukhova L. An imperative need for further genetic studies of alopecia areata. J Investig Dermatol Symp Proc. 2020;20:S22–7.
   PubMedGoogle Scholar
• Talmud PJ, Futema M, Humphries SE. The genetic architecture of the familial hyperlipidaemia syndromes: rare mutations and common variants in multiple genes. Curr Opin Lipidol. 2014;25:274–281.
   PubMedGoogle Scholar
• Almlof JC, Nystedt S, Leonard D, et al. Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus erythematosus. Hum Genet. 2019;138:141–150.
   PubMed Web of Science ®Google Scholar
• Beaudoin M, Goyette P, Boucher G, et al. Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genet. 2013;9:e1003723.
   PubMed Web of Science ®Google Scholar
• Diogo D, Kurreeman F, Stahl EA, et al. Rare, low-frequency, and common variants in the protein-coding sequence of biological candidate genes from GWASs contribute to risk of rheumatoid arthritis. Am J Hum Genet. 2013;92:15–27.
   PubMedGoogle Scholar
• Rivas MA, Beaudoin M, Gardet A, et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet. 2011;43:1066–1073.
   PubMed Web of Science ®Google Scholar
• Thaventhiran JED, Lango Allen H, Burren OS, et al. Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature. 2020;583:90–95.
   PubMed Web of Science ®Google Scholar
• Johnson MB, Patel KA, De Franco E, et al. A type 1 diabetes genetic risk score can discriminate monogenic autoimmunity with diabetes from early-onset clustering of polygenic autoimmunity with diabetes. Diabetologia. 2018;61:862–869.
   PubMedGoogle Scholar
• Christiansen M, Offersen R, Jensen JMB, et al. Identification of novel genetic variants in CVID patients with autoimmunity, autoinflammation, or malignancy. Front Immunol. 2019;10:3022.
   PubMedGoogle Scholar
• Mucha S, Baurecht H, Novak N, et al. Protein-coding variants contribute to the risk of atopic dermatitis and skin-specific gene expression. J Allergy Clin Immunol. 2020;145:1208–1218.
   PubMedGoogle Scholar
• Blair DR, Lyttle CS, Mortensen JM, et al. A nondegenerate code of deleterious variants in Mendelian loci contributes to complex disease risk. Cell. 2013;155:70–80.
   PubMedGoogle Scholar
• Freund MK, Burch KS, Shi H, et al. Phenotype-specific enrichment of Mendelian disorder genes near GWAS regions across 62 complex traits. Am J Hum Genet. 2018;103:535–552.
   PubMedGoogle Scholar
• Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013;12:581–594.
   PubMed Web of Science ®Google Scholar
• Timpson NJ, Greenwood CMT, Soranzo N, et al. Genetic architecture: the shape of the genetic contribution to human traits and disease. Nat Rev Genet. 2018;19:110–124.
   PubMedGoogle Scholar
• Orlova EM, Sozaeva LS, Kareva MA, et al. Expanding the phenotypic and genotypic landscape of autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab. 2017;102(9):3546–3556.
   PubMed Web of Science ®Google Scholar
• Zaremehrjardi F, Baniadam L, Seif F, et al. A patient with CTLA-4 haploinsufficiency with multiple autoimmune presentations: a case report. Iran J Immunol. 2020;17:244–249.
   PubMedGoogle Scholar
• Barzaghi F, Amaya Hernandez LC, Neven B, et al. Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: an international multicenter retrospective study. J Allergy Clin Immunol. 2018;141:1036–49 e5.
   PubMed Web of Science ®Google Scholar
• Klemann C, Camacho-Ordonez N, Yang L, et al. Clinical and immunological phenotype of patients with primary immunodeficiency due to damaging mutations in NFKB2. Front Immunol. 2019;10:297.
   PubMed Web of Science ®Google Scholar
• Schwab C, Gabrysch A, Olbrich P, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. J Allergy Clin Immunol. 2018;142:1932–1946.
   PubMed Web of Science ®Google Scholar
• Flanagan SE, Haapaniemi E, Russell MA, et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet. 2014;46:812–814.
   PubMed Web of Science ®Google Scholar
• Martinez-Mir A, Zlotogorski A, Gordon D, et al. Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet. 2007;80:316–328.
   PubMed Web of Science ®Google Scholar
• Fischer J, Degenhardt F, Hofmann A, et al. Genomewide analysis of copy number variants in alopecia areata in a Central European cohort reveals association with MCHR2. Exp Dermatol. 2017;26:536–541.
   PubMedGoogle Scholar
• Petukhova L, Patel AV, Rigo RK, et al. Integrative analysis of rare copy number variants and gene expression data in alopecia areata implicates an aetiological role for autophagy. Exp Dermatol. 2020;29:243–253.
   PubMed Web of Science ®Google Scholar
• Lee S, Paik SH, Kim HJ, et al. Exomic sequencing of immune-related genes reveals novel candidate variants associated with alopecia universalis. PLoS One. 2013;8:e53613.
   PubMed Web of Science ®Google Scholar
• Shin JM, Kim KH, and Kim SM, et al. Exome sequencing reveals novel candidate gene variants associated with clinical characteristics in alopecia areata patients. J Dermatol Sci. 2020;99:216–220.
   PubMedGoogle Scholar
• Erjavec SO, Gelfman S, Abdelaziz AR, et al. Whole exome sequencing in alopecia areata identifies rare variants in KRT82. Nat Commun. 2022;13:800.
   PubMedGoogle Scholar
• Suarez-Farinas M, Ungar B, and Noda S, et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J Allergy Clin Immunol. 2015;136:1277–1287.
   PubMed Web of Science ®Google Scholar
• Subramanya RD, Coda AB, Sinha AA. Transcriptional profiling in alopecia areata defines immune and cell cycle control related genes within disease-specific signatures. Genomics. 2010;96:146–153.
   PubMed Web of Science ®Google Scholar
• McPhee CG, Duncan FJ, Silva KA, et al. Increased expression of Cxcr3 and its ligands, Cxcl9 and Cxcl10, during the development of alopecia areata in the mouse. J Invest Dermatol. 2012;132:1736–1738.
   PubMedGoogle Scholar
• Carroll JM, McElwee KJ, EK L, et al. Gene array profiling and immunomodulation studies define a cell-mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans. J Invest Dermatol. 2002;119:392–402.
   PubMed Web of Science ®Google Scholar
• Jabbari A, Cerise JE, Chen JC, et al. Molecular signatures define alopecia areata subtypes and transcriptional biomarkers. EBioMedicine. 2016;7:240–247.
   PubMedGoogle Scholar
• Fuentes-Duculan J, Gulati N, Bonifacio KM, et al. Biomarkers of alopecia areata disease activity and response to corticosteroid treatment. Exp Dermatol. 2016;25:282–286.
   PubMedGoogle Scholar
• Czarnowicki T, He HY, Wen HC, et al. Alopecia areata is characterized by expansion of circulating Th2/Tc2/Th22, within the skin-homing and systemic T-cell populations. Allergy. 2018;73:713–723.
   PubMed Web of Science ®Google Scholar
• Song T, Pavel AB, Wen HC, et al. An integrated model of alopecia areata biomarkers highlights both TH1 and TH2 upregulation. J Allergy Clin Immunol. 2018;142:1631–4 e13.
   PubMedGoogle Scholar
• Smogorzewski J, Sierro T, Compoginis G, et al. Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab. JAAD Case Rep. 2019;5:116–117.
   PubMedGoogle Scholar
• Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016 22;1:e89776.
   PubMed Web of Science ®Google Scholar
• Mackay-Wiggan J, Jabbari A, Nguyen N, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016 22;1:e89790.
   PubMed Web of Science ®Google Scholar
• Jabbari A, Sansaricq F, Cerise J, et al. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J Invest Dermatol. 2018;138:1539–1545.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Pavel AB, and Diaz A, et al. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol. 2022;149:1318–1328.
   PubMedGoogle Scholar
• Chen JC, Cerise JE, Jabbari A, et al. Master regulators of infiltrate recruitment in autoimmune disease identified through network-based molecular deconvolution. Cell Syst. 2015;1:326–337.
   PubMedGoogle Scholar
• Chen JC, Dai Z, Christiano AM. Regulatory network analysis defines unique drug mechanisms of action and facilitates patient-drug matching in alopecia areata clinical trials. Comput Struct Biotechnol J. 2021;19:4751–4758.
   PubMed Web of Science ®Google Scholar
• Zhang T, and Nie Y. Prediction of the risk of alopecia areata progressing to alopecia totalis and alopecia universalis: biomarker development with bioinformatics analysis and machine learning. Dermatology. 2022;238:386–396.
   PubMedGoogle Scholar
• Glickman JW, Dubin C, Dahabreh D, et al. An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata. Allergy. 2021;76:3053–3065.
   PubMedGoogle Scholar
• Wells PM, Adebayo AS, Bowyer RCE, et al. Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional study. Lancet Rheumatol. 2020;2:e418–27.
   PubMedGoogle Scholar
• Polak-Witka K, Rudnicka L, Blume-Peytavi U, et al. The role of the microbiome in scalp hair follicle biology and disease. Exp Dermatol. 2020;29:286–294.
   PubMedGoogle Scholar
• Lousada MB, Lachnit T, Edelkamp J, et al. Exploring the human hair follicle microbiome. Br J Dermatol. 2021;184:802–815.
   PubMed Web of Science ®Google Scholar
• Colucci R, Moretti S. Implication of human bacterial gut microbiota on immune-mediated and autoimmune dermatological diseases and their comorbidities: a narrative review. Dermatol Ther (Heidelb). 2021;11:363–384.
   PubMedGoogle Scholar
• Rebello D, Wang E, Yen E, et al. Hair growth in two alopecia patients after fecal microbiota transplant. ACG Case Rep J. 2017;4:e107.
   PubMed Web of Science ®Google Scholar
• Xie WR, Yang XY, Xia HH, et al. Hair regrowth following fecal microbiota transplantation in an elderly patient with alopecia areata: a case report and review of the literature. World J Clin Cases. 2019;7:3074–3081.
   PubMedGoogle Scholar
• Moreno-Arrones OM, Serrano-Villar S, Perez-Brocal V, et al. Analysis of the gut microbiota in alopecia areata: identification of bacterial biomarkers. J Eur Acad Dermatol Venereol. 2020;34:400–405.
   PubMed Web of Science ®Google Scholar
• Rangu S, Lee JJ, Hu W, et al. Understanding the gut microbiota in pediatric patients with alopecia areata and their siblings: a pilot study. JID Innov. 2021; 1: 100051.
   PubMedGoogle Scholar
• Lu J, Zhang P, Hu R, et al. Gut microbiota characterization in Chinese patients with alopecia areata. J Dermatol Sci. 2021;102:109–115.
   PubMed Web of Science ®Google Scholar
• Pinto D, Sorbellini E, Marzani B, et al. Scalp bacterial shift in Alopecia areata. PLoS One. 2019;14:e0215206.
   PubMedGoogle Scholar
• Pinto D, Calabrese FM, De Angelis M, et al. Predictive metagenomic profiling, urine metabolomics, and human marker gene expression as an integrated approach to study alopecia areata. Front Cell Infect Microbiol. 2020;10:146.
   PubMedGoogle Scholar
• Zhou C, Li X, and Wang C, et al. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol. 2021;61:403–423.
   PubMed Web of Science ®Google Scholar
• Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78:15–24.
   PubMed Web of Science ®Google Scholar
• Trueb RM, Dias M. Alopecia areata: a comprehensive review of pathogenesis and management. Clin Rev Allergy Immunol. 2018;54:68–87.
   PubMed Web of Science ®Google Scholar
• Renert-Yuval Y, and Guttman-Yassky E. The changing landscape of alopecia areata: the therapeutic paradigm. Adv Ther. 2017;34:1594–1609.
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Kositkuljorn C, Mahasaksiri T, et al. A comparison of the efficacy and tolerability of three corticosteroid treatment regimens in patients with alopecia areata. J Dermatolog Treat. 2022;33:756–761.
   PubMedGoogle Scholar
• Lee S, Kim BJ, Lee YB, et al. Hair regrowth outcomes of contact immunotherapy for patients with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol. 2018;154:1145–1151.
   PubMed Web of Science ®Google Scholar
• Zerbinati N, Esposito C, D’Este E, et al. Topical immunotherapy of alopecia areata: a Large Retrospective Study. Dermatol Ther (Heidelb). 2018;8:101–110.
   PubMedGoogle Scholar
• Ortolan LS, Kim SR, Crotts S, et al. IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans. J Allergy Clin Immunol. 2019;144:1731–4 e1.
   PubMedGoogle Scholar
• Mikhaylov D, Pavel A, Yao C, et al. A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata. Arch Dermatol Res. 2019;311:29–36.
   PubMed Web of Science ®Google Scholar
• Ismail FF, Sinclair R. JAK inhibition in the treatment of alopecia areata - a promising new dawn? Expert Rev Clin Pharmacol. 2020;13:43–51.
   PubMed Web of Science ®Google Scholar
• Steele L, Lee HL, Maruthappu T, et al. The status and outcomes of registered clinical trials for Janus kinase inhibitors in alopecia areata: are unpublished trials being overlooked? Clin Exp Dermatol. 2021;46:1290–1292.
   PubMedGoogle Scholar
• Dillon KL. A comprehensive literature review of jak inhibitors in treatment of alopecia areata. Clin Cosmet Investig Dermatol. 2021;14:691–714.
   PubMed Web of Science ®Google Scholar
• Yu DA, Kim YE, Kwon O, et al. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: a systematic review and meta-analysis. Indian J Dermatol Venereol Leprol. 2021;87:621–627.
   PubMed Web of Science ®Google Scholar
• King B, Guttman-Yassky E, Peeva E, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021;85:379–387.
   PubMed Web of Science ®Google Scholar
• King B, Ko J, Forman S, et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study. J Am Acad Dermatol. 2021;85:847–853.
   PubMed Web of Science ®Google Scholar
• Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33:850–856.
   PubMed Web of Science ®Google Scholar
• Gilhar A, Keren A, Paus R. JAK inhibitors and alopecia areata. Lancet. 2019;393:318–319.
   PubMed Web of Science ®Google Scholar
• Bain KA, McDonald E, Moffat F, et al. Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. Br J Dermatol. 2020;182:130–137.
   PubMed Web of Science ®Google Scholar
• Kridin K, Renert-Yuval Y, Guttman-Yassky E, et al. Alopecia areata is associated with atopic diathesis: results from a population-based study of 51,561 patients. J Allergy Clin Immunol Pract. 2020;8:1323–8 e1.
   PubMedGoogle Scholar
• Guttman-Yassky E, Renert-Yuval Y, and Bares J, et al. Phase 2a randomized clinical trial of dupilumab (anti-IL-4Ralpha) for alopecia areata patients. Allergy. 2022;77:897–906.
   PubMed Web of Science ®Google Scholar
• Nelson MR, Tipney H, Painter JL, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47:856–860. DOI:https://doi.org/10.1038/ng.3314.
   PubMed Web of Science ®Google Scholar
• Shih HP, Zhang X, and Aronov AM. Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. Nat Rev Drug Discov. 2018;17:19–33. DOI: https://doi.org/10.1038/nrd.2017.194
   PubMed Web of Science ®Google Scholar
• Ardlie KG, Guigo R. Data resources for human functional genomics. Curr Opin Syst Biol. 2017;1:75–79.
   PubMedGoogle Scholar
• GTEx Consortium. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45:580–585.
   PubMed Web of Science ®Google Scholar
• ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57–74.
   PubMed Web of Science ®Google Scholar
• Fishilevich S, Nudel R, Rappaport N, et al. GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. Database (Oxford). 2017 Jan 1;2017. DOI:https://doi.org/10.1093/database/bax028
   PubMedGoogle Scholar
• Dekker J, Belmont AS, Guttman M, et al. The 4D nucleome project. Nature. 2017;549:219–226.
   PubMed Web of Science ®Google Scholar
• Roadmap EpigenomicsConsortium;Kundaje A, Meuleman W, and Ernst J, et al. Integrative analysis of 111 reference human epigenomes. Nature. 2015;518:317–330.
   PubMedGoogle Scholar
• Polygenic Risk Score Task Force of the International Common Disease Alliance. Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps. Nat Med. 2021;27:1876–1884.
   PubMedGoogle Scholar
• Slunecka JL, van der Zee MD, Beck JJ, et al. Implementation and implications for polygenic risk scores in healthcare. Hum Genomics. 2021;15:46.
   PubMed Web of Science ®Google Scholar
• Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet. 2018;19:581–590.
   PubMed Web of Science ®Google Scholar
• Dai Z, Chen J, and Chang Y, et al. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata. JCI Insight. 2021;6:e142205.
   PubMed Web of Science ®Google Scholar
• Dai Z, Wang EHC, Petukhova L, et al. Blockade of IL-7 signaling suppresses inflammatory responses and reverses alopecia areata in C3H/HeJ mice. Sci Adv. 2021;7. DOI:https://doi.org/10.1126/sciadv.abd1866.
   Google Scholar
• Dai Z, Xing L, Cerise J, et al. CXCR3 blockade inhibits t cell migration into the skin and prevents development of alopecia areata. J Immunol. 2016;197:1089–1099.
   PubMedGoogle Scholar
• Gao Z, Jin YQ, Wu W. SOCS3 treatment prevents the development of alopecia areata by inhibiting CD8+ T cell-mediated autoimmune destruction. Oncotarget. 2017;8:33432–33443.
   PubMedGoogle Scholar
• Hashimoto K, Yamada Y, Sekiguchi K, et al. NLRP3 inflammasome activation contributes to development of alopecia areata in C3H/HeJ mice. Exp Dermatol. 2021;31:133–142.
   PubMedGoogle Scholar
• Yuan X, Tang Y, Zhao Z, et al. Identification and verification of EOMEs regulated network in alopecia areata. Int Immunopharmacol. 2020;84:106544.
   PubMedGoogle Scholar
• Borcherding N, Crotts SB, Ortolan LS, et al. A transcriptomic map of murine and human alopecia areata. JCI Insight. 2020;5. DOI:https://doi.org/10.1172/jci.insight.137424.
   Google Scholar
• Zhao M, Liang G, Wu X, et al. Abnormal epigenetic modifications in peripheral blood mononuclear cells from patients with alopecia areata. Br J Dermatol. 2012;166:226–273.
   PubMedGoogle Scholar
• Thanomkitti K, Kanlaya R, Fong-Ngern K, et al. Differential proteomics of lesional vs. non-lesional biopsies revealed non-immune mechanisms of alopecia areata. Sci Rep. 2018;8:521.
   PubMedGoogle Scholar